- Upper respiratory tract infections including acute otitis media, pharyngitis, tonsillitis, acute exacerbation of chronic bronchitis (AECB), and acute maxillary sinusitis
- Acute uncomplicated urethral and cervical gonorrhea and ano-rectal gonorrhea (females) caused by N. gonorrhoeae (no longer recommended by CDC) 
- Uncomplicated skin and skin-structure infections S. aureus (MSSA) or S. pyogenes.
- Uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, P. mirabilis, or S. saprophyticus.
- Community-acquired pneumonia (CAP) caused by S. pneumoniae or H. influenzae
NON-FDA APPROVED USES
- Prophylaxis in neutropenic fever in patients who are intolerant of fluoroquinolones
- Oral alternative therapy for pyelonephritis without bacteremia in patients who are resistant to fluoroquinolones or trimethoprim/sulfamethoxazole.
- IDSA recommends that if oral β-lactams are to be empirically used, initial intravenous dose of a long-acting parenteral antimicrobial such as 1 g of ceftriaxone or a consolidated 24-h dose of an aminoglycoside be administered first.
There's more to see -- the rest of this topic is available only to subscribers.